36-year-old man with productive cough and diffuse rash

Mayo Clinic Proceedings

Volumn 81, Issue 7, 2006, Pages 945-948

  Kumar, Gautam ^a   Fadel, Hind J ^a   Beckman, Thomas J ^b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; CONTINUING EDUCATION; COUGHING; HUMAN; INCIDENCE; MALE; MULTIPLE CHOICE TEST; RASH; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

EID: 33745608465     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.7.945     Document Type: Article

References (25)

1. Niederman MS, Mandell LA, Anzueto A, et al, American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730-1754.
2. Byrd RP Jr, Vasquez J, Roy TM. Respiratory manifestations of tickborne diseases in the Southeastern United States. South Med J. 1997;90:1-4.
3. Treadwell TA, Holman RC, Clarke MJ, Krebs JW, Paddock CD, Childs JE. Rocky Mountain spotted fever in the United States, 1993-1996. Am J Trop Med Hyg. 2000;63:21-26.
4. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92-96.
5. Hebra F. Erythema exsudativum multiforme. In: Kaiserliche Akademie der Wissenschaften, ed. Atlas der Hautkrankheiten. Vienna, Austria: Kaiserliche Akademie der Wissenschaften; 1866;6:55-57.
6. Stevens AM, Johnson FC. New eruptive fever associated with stomatitis and ophthalmia: 2 cases in children. Am J Dis Child. 1922;24:526-533.
7. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995; 333:1600-1607.
8. Saiag P, Caumes E, Chosidow O, Revuz J, Roujeau JC. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol. 1992;26:567-574.
9. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136:323-327.
10. Schulz JT, Sheridan RL, Ryan CM, MacKool B, Tompkins RG. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil. 2000; 21:199-204.
11. Hynes AY, Kafkala C, Daoud YJ, Foster CS. Controversy in the use of high-dose systemic steroids in the acute care of patients with Stevens-Johnson syndrome. Int Ophthalmol Clin. 2005;45:25-48.
12. Prins C, Vittorio C, Padilla RS, et al. Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study. Dermatology. 2003;207:96-99.
13. Trautmann A, Klein CE, Kampgen E, Brocker EB. Severe bullous drug reactions treated successfully with cyclophosphamide. Br J Dermatol. 1998; 139:1127-1128.
14. French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol. 2006 Apr;6:543-549. Epub 2005 Dec 19.
15. Chan LS, Soong HK, Foster CS, Hammerberg C, Cooper KD. Ocular cicatricial pemphigoid occurring as a sequela of Stevens-Johnson syndrome. JAMA. 1991;266:1543-1546.
16. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol. 1996;49:769-773.
17. Roujeau JC, Guillaume JC, Fabre JP, Penso D, Flechet ML, Girre JP. Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981-1985. Arch Dermatol. 1990;126:37-42.
18. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126:43-47.
19. Paul C, Wolkenstein P, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol. 1996;134: 710-714.
20. Correia O, Delgado L, Ramos JP, Resende C, Torrinha JA. Cutaneous T-cell recruitment in toxic epidermal necrolysis: further evidence of CD8+ lymphocyte involvement. Arch Dermatol. 1993;129:466-468.
21. Wolkenstein P, Charue D, Laurent P, Revuz J, Roujeau JC, Bagot M. Metabolic predisposition to cutaneous adverse drug reactions: role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch Dermatol. 1995;131:544-551.
22. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490-493.
23. Nagata S. Apoptosis by death factor. Cell. 1997;88:355-365.
24. Tay YK, Huff JC, Weston WL. Mycoplasma pneumonia infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). J Am Acad Dermatol. 1996;35:757-760.
25. Communicable Disease Surveillance Centre (Public Health Laboratory Service) and Communicable Disease (Scotland) Unit. Mycoplasma pneumoniae. BMJ. 1978;1:726.